1. Market Research
  2. > Pathology
82 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Global Lymphoma Drugs Market 2017-2021

  • $ 2500
  • June 2017
  • 86 pages

The aim of lymphoma treatment is to get rid of the lymphoma cells.

  • Cancer
  • Lymphoma
  • Celgene Corporation
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Sexually Transmitted Disease
  • United States
  • Celgene Corporation

NHL: Diffuse large Bcell lymphoma

  • $ 5000
  • May 2016
  • 219 pages

Immunophenotyping also needs to be robust enough to distinguish the disease from other lymphomas which resemble DLBCL in morphology, such as mantle cell lymphoma and Burkitt' s lymphoma.

  • Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Celgene Corporation

NHL: Follicular lymphoma

  • $ 5000
  • April 2016
  • 252 pages

NHL: Follicular lymphoma Disease Coverage | Treatment: Follicular Lymphoma practices.

  • Healthcare
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Celgene Corporation

NHL: Mantle cell lymphoma

  • $ 5000
  • April 2016
  • 214 pages

Lymphoma Association (2016) Mantle cell lymphoma.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Celgene Corporation

Global Chemotherapy Drugs Market - Opportunities and Forecast (2013-2023)

  • $ 2200
  • March 2019
  • 200 pages

Lymphoma Gastrointestine Others Figure ##: Types of cancer for which clinical trials using chemotherapy drugs treatment are being conducted ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% Source: U. S Clinical Trials Registry GLOBAL THERAPEUTIC CHEMOTHERAPY DRUGS MARKET FIGURE ##: GLOBAL

  • Cancer
  • Chemotherapy
  • Lymphoma
  • Therapy
  • Celgene Corporation

T-Cell Immunotherapy Market (3rd Edition), 2018-2030

  • $ 3499
  • April 2018
  • 850 pages

LEUKEMIA AND LYMPHOMA ##. ##. ##. ##.

  • Immunotherapy
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Celgene Corporation

Vaginal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 351 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • United States
  • Celgene Corporation

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 403 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Celgene Corporation

Global Regenerative Medicine Market - Opportunities and Forecast

  • $ 2400
  • August 2019
  • 326 pages

This strategic acquisition will further promote Gilead as an industry leader in refractory large B-cell lymphoma after two or more lines of therapy.

  • Biopharmaceutical
  • Lymphoma
  • Regenerative Medicine
  • Market Size
  • Celgene Corporation

Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029

  • $ 10995
  • June 2020
  • 139 pages

LYMPHOMAS GO-2032C GSK-## CHIMERIX INC EXCELLTHERA INC FUJIFILM HOLDINGS CORP FUJIFILM HOLDINGS CORP AVEO ONCOLOGY INC MACROGENICS INC SYNIMMUNE GMBH CHONGQING PRECISION BIOTECH CO LTD PERSONGEN BIOMEDICINE SUZHOU CO LTD PERSONGEN BIOMEDICINE SUZHOU CO LTD GENUS ONCOLOGY LLC GLAXOSMITH

  • Chemotherapy
  • Leukemia
  • Lymphoma
  • Therapy
  • Celgene Corporation

Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)

  • $ 1000
  • July 2018
  • 79 pages

Celgene also gains full global rights to JCAR## (lisocabtagene maraleucel; liso-cel), a CD-## targeted CAR-T therapy currently in pivotal trials for relapsed and/ or refractory diffuse large B-cell lymphoma (DLBCL).

  • Lymphoma
  • Therapy
  • World
  • Bristol-Myers Squibb Company
  • Celgene Corporation

Potential Pipeline Disruptors

  • $ 4200
  • May 2017
  • 120 pages

FOLLICULAR LYMPHOMA TENDS TO BE INDOLENT AND DIFFUSE LYMPHOMA TENDS TO BE AGGRESSIVE.

  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Celgene Corporation

Chimeric Antigen Receptor Cell Therapy

  • $ 7995
  • February 2019
  • 108 pages

This doesn' t appear, to me, to be a major game-changer, at least for lymphoma.

  • Cell Therapy
  • Immunotherapy
  • Lymphoma
  • Celgene Corporation
  • Novartis AG

Myelodysplastic Syndromes: Opportunity Analysis and Forecasts to 2028

  • $ 10995
  • May 2020
  • 193 pages

GAMIDA HAS AN ONGOING PHASE III, MULTICENTER, RANDOMIZED, REGISTRATIONAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF TRANSPLANTATION WITH OMIDUBICEL VERSUS TRADITIONAL UCBT IN PATIENTS WITH LEUKEMIA, LYMPHOMA, AND KOLs noted that patients with TP##mutant MDS have exceptionally poor prognose

  • Blood Disease
  • Lymphoma
  • Therapy
  • United States
  • Celgene Corporation

Global Gene Therapy Market Report - 2026

  • $ 3849
  • July 2018
  • 105 pages

Lymphoma, B-Cell Lymphoma Cd##+ Diffuse Large B-Cell Lymphoma Undisclosed (Expected Oncology) Prostate Cancer, Lung Cancer Phase ## CTL## CAR-T Phase ##I BiTE platform CAR-T Phase ## LADD iMultiple Myelomauno-oncology platform Up to ## gene therapies including S##A## Phase ##

  • Gene Therapy
  • Lymphoma
  • Therapy
  • Boehringer Ingelheim GmbH
  • Celgene Corporation

Oncology drug report - Adcetris - brentuximab vedotin - 2011-2015 analysis; 2016-2021 expectations

  • $ 513
  • November 2016
  • 75 pages

Rituxan is the first monoclonal antibody approved for lymphomas.

  • Lymphoma
  • Therapy
  • North America
  • United States
  • Celgene Corporation

Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)

  • $ 6400
  • October 2018
  • 36 pages

lymphoma, solid tumors IPF Phase I completed Phase I Pirfenidone (inhaled) Green text signifies updates from last quarter Early Stage Pipeline ' Watch List' PXS-##A PXS-##K Drug Plasminogen (Ryplazim) Developer Prometic Synairgen & Pharmaxis Synairgen & Pharmaxis RP##

  • Pharmaceutical
  • Therapy
  • United States
  • Celgene Corporation
  • ProMetic Life Sciences Inc.

Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations

  • $ 513
  • November 2016
  • 71 pages

REVLIMID IS NOT APPROVED FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA.

  • Cancer Hormonal Therapy
  • Lymphoma
  • Therapy
  • United States
  • Celgene Corporation

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth

  • $ 4995
  • September 2018
  • 141 pages

However, Humira is packaged with a boxed warning relating to an increased risk of severe infections, such as tuberculosis and bacterial sepsis, and an increased risk of malignancy, such as lymphomas, for patients taking this drug.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatological Treatment
  • Lymphoma
  • Celgene Corporation
View report >

Pathology Statistics - Forecast

  • December 2018
  • 10 pages

Celgene expects lymphoma to be a major growth driver for Revlimid by 2020 and beyond.

  • Lymphoma
  • Medical Biotechnology
  • Pathology
  • Demand
  • Celgene Corporation

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on